et al. Probability of finding HLA-matched unrelated marrow donors. Transplantation.
1988;45714- 718Link to Article
et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med.
1993;328593- 602Link to Article
et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first 2 years. Ann Intern Med.
1993;119207- 214Link to Article
ED Anti-leukemic effects of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med.
1979;3001068- 1073Link to Article
et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75555- 562
GW Evidence of a graft versus lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77649- 653
et al. for the European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia, Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood. 1995;862041- 2050
et al. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995;231553- 1562
et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996;872195- 2204
et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15433- 444
et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease. Blood. 1998;91756- 763
TR Nonmyeloablative allogeneric stem cell transplant strategies and the role of mixed chemerism. Oncologist.
2000;5215- 223Link to Article
et al. Transplant-lite: induction of graft-versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;162817- 2824
S Reinventing bone marrow transplantation: nonmyeloablative preparative regimen and induction of graft versus malignancy effect. Oncology. 1999;13621- 628
Not Available, The International Bone Marrow Transplant Registry (IBMTR)/Autologuous Blood and Marrow Transplant Registry (ABMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) meeting. Leuk Lymphoma. 2000;37- 12
SA Nonmyeloablative stem cell transplantation: lessons from the first generation trials. Leuk Lymphoma. 1999;23- 7
et al. Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: long-term follow-up. Blood. 1991;782451- 2455
et al. Bone marrow transplantation for severe aplastic anemia: effect of a preparative regimen of cyclophosphamide low-dose total lymphoid irradiation and post-transplant cyclosporine-methotrexate therapy. Transplantation.
1990;49720- 724Link to Article
et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73606- 613
et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84941- 949
et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;842036- 2043
GW Indications for bone marrow transplantation. DATELINE: Issues Transplant. 1992;31- 20
LG Immune recovery after bone marrow transplantation. Hematol Oncol Clin North Am. 1990;4659- 675
et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med.
1992;326845- 851Link to Article
JD Viral infections in the compromised host. Brian
Peds.Current Therapy in Hematology-Oncology 1985-1986; Philadelphia, Pa BC Decker Inc1985;102- 108
J Viral infections associated with bone marrow transplantation. Hematol Oncol Clin North Am. 1990;4603- 623
et al. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med.
1981;30563- 67Link to Article
et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood. 1991;78246- 250
et al. Intravenous immunoglobulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med.
1987;10612- 18Link to Article
et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med.
1986;3141006- 1010Link to Article
et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med.
1993;118173- 178Link to Article
et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial. Ann Intern Med.
1993;118179- 184Link to Article
et al. for The City of Hope-Stanford-Syntex CMV Study Group, A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med.
1991;3241005- 1011Link to Article
et al. Interstitial pneumonitis after bone marrow transplantation: assessment of risk factors. Ann Intern Med.
1986;104168- 175Link to Article
et al. Interstitial pneumonitis after allogeneic bone marrow transplantation: nine-year experience at a single institution. Medicine (Baltimore).
1988;67175- 186Link to Article
et al. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis.
1992;166473- 479Link to Article
SI The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;853005- 3020
et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med.
1993;118255- 267Link to Article
H Early drop in protein C and antithrombin III levels is a predictor for the development of venoocclusive disease in patients undergoing bone marrow transplantation [abstract]. Blood. 1994;84335a
et al. Transjugular liver biopsy in bone marrow transplantation. Bone Marrow Transplant. 1993;1121- 26
GB Utility of transvenous liver biopsy and hepatic venous pressure measurements in Seattle marrow transplant recipients [abstract]. Exp Hematol. 1990;18699
et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol. 1993;111729- 1736
RE Venoocclusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplant. 1990;5439- 441
et al. Recombinant human tissue plasminogen activator for the treatment of established severe venoocclusive disease of the liver after bone marrow transplantation. Blood. 1992;802458- 2462
et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92737- 744
et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood. 1991;781205- 1211
et al. Pentoxifylline did not prevent transplant-related toxicity in 31 consecutive allogeneic bone marrow transplant recipients [letter]. Blood. 1992;802683- 2684
et al. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood. 1993;822025- 2030
et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood. 1992;792834- 2840
et al. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1992;10367- 372
HJ Graft-versus-host disease. N Engl J Med.
1991;324667- 674Link to Article
RE The biology of graft-versus-host reactions. Harvey Lect. 1966-1967;6221- 78
et al. Graft-versus-host disease in cyclosporine treated rats following syngeneic and autologous bone marrow reconstitution. J Exp Med.
1983;1581- 8Link to Article
et al. Autologous graft-versus-host disease: a new frontier in immunotherapy. Bone Marrow Transplant. 1992;1016- 21
JL Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;802964- 2968
JH Inhibition of dysregulated cytokines to control acute graft-versus-host disease. Hematol Oncol Ann. 1994;2341- 346
et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood. 1994;841320- 1327
et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood. 1994;841342- 1348
et al. Risk factors for acute graft-versus-host disease. Br J Haematol.
1987;67397- 406Link to Article
et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood. 1992;801838- 1845
et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood. 1989;731729- 1734
et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med.
1993;3291225- 1230Link to Article
et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft versus host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;922303- 2314
et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med.
1990;323705- 712Link to Article
et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: beneficial effect of a protective environment. N Engl J Med.
1983;308302- 307Link to Article
et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood. 1991;782139- 2149
et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;761464- 1472
et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood. 1991;771821- 1828
et al. Use of an anti-pan T-lymphocyte ricin, a chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood. 1990;751426- 1432
et al. Myasthenia gravis after bone-marrow transplantation: evidence for a donor origin. N Engl J Med.
1983;3091565- 1568Link to Article
et al. Prednisone and azathioprine compared with prednisone alone and placebo for the treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72546- 554
et al. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-versus-host disease and low serum IgG. Blood. 1988;72621- 627
et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood. 1995;863604- 3609
et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989;741428- 1435
et al. Risk factors for chronic graft-versus-host-disease after HLA-identical sibling bone marrow transplantation. Blood. 1990;752459- 2464
et al. Thyroid and pituitary function following allogenic bone marrow transplantation. Arch Intern Med.
1988;1481066- 1071Link to Article
et al. Autoimmune hyperthyroidism associated with chronic graft-versus-host disease. Transplantation.
1987;44463- 464Link to Article
JE Implications of cancer therapy to the head and neck on growth and development and other delayed effects. Fox
CCeds.Consensus Development Conference on Oral Complications of Cancer Therapies Diagnosis, Prevention, and Treatment. Bethesda, Md Public Health Service1990;163- 167NCI monograph 9
JEfor the Seattle Marrow Transplant Team, The impact of marrow transplant preparative regimens on subsequent growth and development. Semin Hematol. 1991;28244- 249
JE Impact of marrow transplantation on subsequent fertility. Bern
Feds.Hematologic Disorders in Maternal-Fetal Medicine. New York, NY Wiley-Liss Inc1990;327- 334
et al. Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation. Int J Radiat Oncol Biol Phys.
1984;10957- 964Link to Article
et al. Obstructive lung disease after allogeneic marrow transplantation: clinical presentation and course. Ann Intern Med.
1989;111368- 376Link to Article
et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med.
1989;321784- 789Link to Article
et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood. 1988;72520- 529
et al. Malignant diseases after allogeneic bone marrow transplantation: the case for assessment of risk factors. Br J Haematol.
1992;80427- 430Link to Article
et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Ann Intern Med.
1999;131738- 744Link to Article
et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med.
1983;3091347- 1353Link to Article
et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol. 1992;101723- 1729
et al. Bone marrow transplantation for Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood. 1992;793067- 3070
et al. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission. Blood. 1991;781923- 1927
et al. Impact of disease duration and prior treatment on outcome of bone marrow transplants for chronic myelogenous leukemia (CML) [abstract]. Blood. 1992;80
et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy 2. Blood. 1992;801352- 1357
et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood. 1993;82398- 407
et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82677- 681
et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 1995;131312- 1322
et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol. 1992;101690- 1695
et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood. 1994;841050- 1055
et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med.
1990;322417- 421Link to Article
G Bone marrow transplantation in five children with sickle cell anaemia. Lancet.
1988;11427- 1428Link to Article
W Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. Biol Blood Marrow Transplant. 1997;3310- 315
G Bone marrow transplantation for sickle cell disease: the European experience. Am J Pediatr Hematol Oncol. 1994;1618- 21
MC Bone marrow transplantation for sickle cell disease: where do we go from here? J Pediatr Hematol Oncol.
1999;21467- 474Link to Article
S Autoimmune diseases as stem cell disorders: normal stem cell transplant for their treatment. Int J Mol Med. 1998;15- 16
A Autologuous peripheral blood stem and progenitor (CD34+
) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome. Lupus.
1998;7492- 494Link to Article
AM Stem cell transplantation for severe autoimmune diseases: progress and problems. Haematologica. 1998;83733- 743
RE Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood. 1994;843603- 3612
et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med.
1993;329757- 761Link to Article
et al. Relapse of leukemia after bone marrow transplantation: effect of second myeloablative therapy. Bone Marrow Transplant. 1992;9205- 209
et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol. 1993;11304- 313